LAB #: F000000-0000-0
PATIENT: Sample Patient
ID: P00000000
SEX: Female
DOB: 01/01/2000 AGE: 13

CLIENT #: 12345
DOCTOR:
Doctor's Data, Inc.
3755 Illinois Ave.
St. Charles, IL 60174 USA

Comprehensive Stool Analysis

BACTERIOLOGY CULTURE

Expected/Beneficial flora	Commensal (Imbalanced) flora	Dysbiotic flora
NG Bacteroides fragilis group		4+ Citrobacter braakii
4+ Bifidobacterium spp.		4+ Klebsiella pneumoniae ssp pneumoniae
3+ Escherichia coli		
3+ Lactobacillus spp.		
4+ Enterococcus spp.		
NG Clostridium spp.		

NG = No Growth

BACTERIA INFORMATION

Expected /Beneficial bacteria make up a significant portion of the total microflora in a healthy & balanced GI tract. These beneficial bacteria have many health-protecting effects in the GI tract including manufacturing vitamins, fermenting fibers, digesting proteins and carbohydrates, and propagating anti-tumor and anti-inflammatory factors.
Clostridia are prevalent flora in a healthy intestine. Clostridium spp. should be considered in the context of balance with other expected/beneficial flora. Absence of clostridia or over abundance relative to other expected/beneficial flora indicates bacterial imbalance. If *C. difficile* associated disease is suspected, a Comprehensive Clostridium culture or toxigenic *C. difficile* DNA test is recommended.
Commensal (Imbalanced) bacteria are usually neither pathogenic nor beneficial to the host GI tract. Imbalances can occur when there are insufficient levels of beneficial bacteria and increased levels of commensal bacteria. Certain commensal bacteria are reported as dysbiotic at higher levels.
Dysbiotic bacteria consist of known pathogenic bacteria and those that have the potential to cause disease in the GI tract. They can be present due to a number of factors including: consumption of contaminated water or food, exposure to chemicals that are toxic to beneficial bacteria; the use of antibiotics, oral contraceptives or other medications; poor fiber intake and high stress levels.

YEAST CULTURE

Normal flora	Dysbiotic flora
	2+ Candida lusitaniae

MICROSCOPIC YEAST

Result:	Expected:
Rare	None - Rare

The microscopic finding of yeast in the stool is helpful in identifying whether there is proliferation of yeast. Rare yeast may be normal; however, yeast observed in higher amounts (few, moderate, or many) is abnormal.

YEAST INFORMATION

Yeast normally can be found in small quantities in the skin, mouth, intestine and mucocutaneous junctions. Overgrowth of yeast can infect virtually every organ system, leading to an extensive array of clinical manifestations. Fungal diarrhea is associated with broad-spectrum antibiotics or alterations of the patient's immune status. Symptoms may include abdominal pain, cramping and irritation. When investigating the presence of yeast, disparity may exist between culturing and microscopic examination. Yeast are not uniformly dispersed throughout the stool, this may lead to undetectable or low levels of yeast identified by microscopy, despite a cultured amount of yeast. Conversely, microscopic examination may reveal a significant amount of yeast present, but no yeast cultured. Yeast does not always survive transit through the intestines rendering it unvialble.

Comments:

Date Collected: **08/17/2013**
Date Received: **08/22/2013**
Date Completed: **09/05/2013**

** **Aeromonas, Campylobacter, Plesiomonas, Salmonella, Shigella, Vibrio, Yersinia, & Edwardsiella tarda** have been specifically tested for and found absent unless reported.*

MALDI-TOF

LAB #: F000000-0000-0
PATIENT: Sample Patient
ID: P000000000
SEX: Female
DOB: 01/01/2000 AGE: 13

CLIENT #: 12345
DOCTOR:
Doctor's Data, Inc.
3755 Illinois Ave.
St. Charles, IL 60174 USA

Comprehensive Stool Analysis

DIGESTION /ABSORPTION

	Within	Outside	Reference Range
Elastase	> 500		> 200 µg/mL
Fat Stain	None		None - Mod
Muscle fibers	None		None - Rare
Vegetable fibers	Rare		None - Few
Carbohydrates	Neg		Neg

Elastase findings can be used for the diagnosis or the exclusion of exocrine pancreatic insufficiency. Correlations between low levels and chronic pancreatitis and cancer have been reported. **Fat Stain:** Microscopic determination of fecal fat using Sudan IV staining is a qualitative procedure utilized to assess fat absorption and to detect steatorrhea. **Muscle fibers** in the stool are an indicator of incomplete digestion. Bloating, flatulence, feelings of "fullness" may be associated with increase in muscle fibers. **Vegetable fibers** in the stool may be indicative of inadequate chewing, or eating "on the run". **Carbohydrates:** The presence of reducing substances in stool specimens can indicate carbohydrate malabsorption.

INFLAMMATION

	Within	Outside	Reference Range
Lysozyme*		631	<= 600 ng/mL
Lactoferrin		7130	< 7.3 µg/mL
White Blood Cells	None		None - Rare
Mucus	Neg		Neg

Lysozyme* is an enzyme secreted at the site of inflammation in the GI tract and elevated levels have been identified in IBD patients. **Lactoferrin** is a quantitative GI specific marker of inflammation used to diagnose and differentiate IBD from IBS and to monitor patient inflammation levels during active and remission phases of IBD. **White Blood Cells** (WBC): in the stool are an indication of an inflammatory process resulting in the infiltration of leukocytes within the intestinal lumen. WBCs are often accompanied by mucus and blood in the stool. **Mucus** in the stool may result from prolonged mucosal irritation or in a response to parasympathetic excitability such as spastic constipation or mucous colitis.

IMMUNOLOGY

	Within	Outside	Reference Range
Secretory IgA*		326	51 - 204mg/dL

Secretory IgA* (sIgA) is secreted by mucosal tissue and represents the first line of defense of the GI mucosa and is central to the normal function of the GI tract as an immune barrier. Elevated levels of sIgA have been associated with an upregulated immune response.

Comments:

Date Collected: **08/17/2013**
Date Received: **08/22/2013**
Date Completed: **09/05/2013**

***For Research Use Only. Not for use in diagnostic procedures.**

LAB #: F000000-0000-0
PATIENT: Sample Patient
ID: P000000000
SEX: Female
DOB: 01/01/2000 AGE: 13

CLIENT #: 12345
DOCTOR:
Doctor's Data, Inc.
3755 Illinois Ave.
St. Charles, IL 60174 USA

Comprehensive Stool Analysis

SHORT CHAIN FATTY ACIDS

	Within	Outside	Reference Range
% Acetate	74		36 - 74 %
% Propionate		8.5	9 - 32 %
% Butyrate	16		9 - 39 %
% Valerate	1.6		1 - 8 %
Butyrate	2.2		0.8 - 3.8 mg/mL
Total SCFA's	14		4 - 14 mg/mL

Short chain fatty acids (SCFAs): SCFAs are the end product of the bacterial fermentation process of dietary fiber by beneficial flora in the gut and play an important role in the health of the GI as well as protecting against intestinal dysbiosis. Lactobacilli and bifidobacteria produce large amounts of short chain fatty acids, which decrease the pH of the intestines and therefore make the environment unsuitable for pathogens, including bacteria and yeast. Studies have shown that SCFAs have numerous implications in maintaining gut physiology. SCFAs decrease inflammation, stimulate healing, and contribute to normal cell metabolism and differentiation. Levels of **Butyrate** and **Total SCFA** in mg/mL are important for assessing overall SCFA production, and are reflective of beneficial flora levels and/or adequate fiber intake.

INTESTINAL HEALTH MARKERS

	Within	Outside	Reference Range
Red Blood Cells	None		None - Rare
pH	6.5		6 - 7.8
Occult Blood	Neg		Neg

Red Blood Cells (RBC) in the stool may be associated with a parasitic or bacterial infection, or an inflammatory bowel condition such as ulcerative colitis. Colorectal cancer, anal fistulas, and hemorrhoids should also be ruled out.
pH: Fecal pH is largely dependent on the fermentation of fiber by the beneficial flora of the gut.
Occult blood: A positive occult blood indicates the presence of free hemoglobin found in the stool, which is released when red blood cells are lysed.

MACROSCOPIC APPEARANCE

	Appearance	Expected
Color	Green	Brown
Consistency	Soft	Formed/Soft

Color: Stool is normally brown because of pigments formed by bacteria acting on bile introduced into the digestive system from the liver. While certain conditions can cause changes in stool color, many changes are harmless and are caused by pigments in foods or dietary supplements. **Consistency:** Stool normally contains about 75% water and ideally should be formed and soft. Stool consistency can vary based upon transit time and water absorption.

LAB #: F000000-0000-0
PATIENT: Sample Patient
ID: P000000000
SEX: Female
AGE: 13

CLIENT #: 12345
DOCTOR:
Doctor's Data, Inc.
3755 Illinois Ave.
St. Charles, IL 60174 USA

Bacterial Susceptibilities: Citrobacter braakii

NATURAL ANTIBACTERIALS



Natural antibacterial agents may be useful for treatment of patients when organisms display in-vitro sensitivity to these agents. The test is performed by using standardized techniques and filter paper disks impregnated with the listed agent. Relative sensitivity is reported for each natural agent based upon the diameter of the zone of inhibition surrounding the disk. Data based on over 5000 individual observations were used to relate the zone size to the activity level of the agent. A scale of relative sensitivity is defined for the natural agents tested.

PRESCRIPTIVE AGENTS

	Resistant	Intermediate	Susceptible
Amoxicillin-Clavulanic Acid	R		
Ampicillin	R		
Cefazolin	R		
Ceftazidime			S
Ciprofloxacin			S
Trimeth-sulfa			S

Susceptible results imply that an infection due to the bacteria may be appropriately treated when the recommended dosage of the tested antimicrobial agent is used.
Intermediate results imply that response rates may be lower than for susceptible bacteria when the tested antimicrobial agent is used.
Resistant results imply that the bacteria will not be inhibited by normal dosage levels of the tested antimicrobial agent.

Comments:
Date Collected: 08/17/2013
Date Received: 08/22/2013
Date Completed: 09/05/2013

Natural antibacterial agent susceptibility testing is intended for research use only. Not for use in diagnostic procedures.

v10.11

LAB #: F000000-0000-0
PATIENT: Sample Patient
ID: P000000000
SEX: Female
AGE: 13

CLIENT #: 12345
DOCTOR:
Doctor's Data, Inc.
3755 Illinois Ave.
St. Charles, IL 60174 USA

Bacterial Susceptibilities: Klebsiella pneumoniae ssp pneumoniae

NATURAL ANTIBACTERIALS



Natural antibacterial agents may be useful for treatment of patients when organisms display in-vitro sensitivity to these agents. The test is performed by using standardized techniques and filter paper disks impregnated with the listed agent. Relative sensitivity is reported for each natural agent based upon the diameter of the zone of inhibition surrounding the disk. Data based on over 5000 individual observations were used to relate the zone size to the activity level of the agent. A scale of relative sensitivity is defined for the natural agents tested.

PRESCRIPTIVE AGENTS

	Resistant	Intermediate	Susceptible
Amoxicillin-Clavulanic Acid			S
Ampicillin	R		
Cefazolin			S
Ceftazidime			S
Ciprofloxacin			S
Trimeth-sulfa			S

Susceptible results imply that an infection due to the bacteria may be appropriately treated when the recommended dosage of the tested antimicrobial agent is used.
Intermediate results imply that response rates may be lower than for susceptible bacteria when the tested antimicrobial agent is used.
Resistant results imply that the bacteria will not be inhibited by normal dosage levels of the tested antimicrobial agent.

Comments:
Date Collected: **08/17/2013**
Date Received: **08/22/2013**
Date Completed: **09/05/2013**

Natural antibacterial agent susceptibility testing is intended for research use only. Not for use in diagnostic procedures.

v10.11

LAB #: F000000-0000-0
PATIENT: Sample Patient
ID: P000000000
SEX: Female
AGE: 13

CLIENT #: 12345
DOCTOR:
Doctor's Data, Inc.
3755 Illinois Ave.
St. Charles, IL 60174 USA

Yeast Susceptibilities: Candida lusitaniae

NATURAL ANTIFUNGALS



Natural antifungal agents may be useful for treatment of patients when organisms display in-vitro sensitivity to these agents. The test is performed by using standardized techniques and filter paper disks impregnated with the listed agent. Relative sensitivity is reported for each natural agent based upon the diameter of the zone of inhibition surrounding the disk. Data based on over 5000 individual observations were used to relate the zone size to the activity level of the agent. A scale of relative sensitivity is defined for the natural agents tested.

NON-ABSORBED ANTIFUNGALS



Non-absorbed antifungals may be useful for treatment of patients when organisms display in-vitro sensitivity to these agents. The test is performed using standardized commercially prepared disks impregnated with Nystatin. Relative sensitivity is reported based upon the diameter of the zone of inhibition surrounding the disk.

AZOLE ANTIFUNGALS

	Resistant	S-DD	Susceptible
Fluconazole			S
Itraconazole			S
Ketoconazole			S

Susceptible results imply that an infection due to the fungus may be appropriately treated when the recommended dosage of the tested antifungal agent is used.
Susceptible - Dose Dependent (S-DD) results imply that an infection due to the fungus may be treated when the highest recommended dosage of the tested antifungal agent is used.
Resistant results imply that the fungus will not be inhibited by normal dosage levels of the tested antifungal agent.

Standardized test interpretive categories established for Candida spp. are used for all yeast isolates.

Comments:
Date Collected: **08/17/2013**
Date Received: **08/22/2013**
Date Completed: **09/05/2013**

Yeast antifungal susceptibility testing is intended for research use only.
Not for use in diagnostic procedures.

v10.11

INTRODUCTION

This analysis of the stool specimen provides fundamental information about the overall gastrointestinal health of the patient. When abnormal microflora or significant aberrations in intestinal health markers are detected, specific interpretive paragraphs are presented. If no significant abnormalities are found, interpretive paragraphs are not presented.

Beneficial Flora

One or more of the expected (beneficial) bacteria are low in this specimen. Beneficial flora include lactobacilli, bifidobacteria, clostridia, Bacteroides fragilis group, enterococci, and some strains of Escherichia coli. The beneficial flora have many health-protecting effects in the gut, and as a consequence, are crucial to the health of the whole organism. Some of the roles of the beneficial flora include digestion of proteins and carbohydrates, manufacture of vitamins and essential fatty acids, increase in the number of immune system cells, break down of bacterial toxins and the conversion of flavinoids into anti-tumor and anti-inflammatory factors. Lactobacilli, bifidobacteria, clostridia, and enterococci secrete lactic acid as well as other acids including acetate, propionate, butyrate, and valerate. This secretion causes a subsequent decrease in intestinal pH, which is crucial in preventing an enteric proliferation of microbial pathogens, including bacteria and yeast. Many GI pathogens thrive in alkaline environments. Lactobacilli also secrete the antifungal and antimicrobial agents lactocidin, lactobacillin, acidolin, and hydrogen peroxide. The beneficial flora of the GI have thus been found useful in the inhibition of microbial pathogens, prevention and treatment of antibiotic associated diarrhea, prevention of traveler's diarrhea, enhancement of immune function, and inhibition of the proliferation of yeast.

In a healthy balanced state of intestinal flora, the beneficial flora make up a significant proportion of the total microflora. Healthy levels of each of the beneficial bacteria are indicated by either a 3+ or 4+ (0 to 4 scale). However, some individuals have low levels of beneficial bacteria and an overgrowth of nonbeneficial (imbalances) or even pathogenic microorganisms (dysbiosis). Often attributed to the use of antibiotics, individuals with low beneficial bacteria may present with chronic symptoms such as irregular transit time, irritable bowel syndrome, bloating, gas, chronic fatigue, headaches, autoimmune diseases (e.g., rheumatoid arthritis), and sensitivities to a variety of foods. Treatment may include the use of probiotic supplements containing various strains of lactobacilli, bifidobacteria and enterococci and consumption of cultured or fermented foods including yogurt, kefir, miso, tempeh and tamari sauce. Polyphenols in green and ginseng tea have been found to increase the numbers of beneficial bacteria. If dysbiosis is present, treatment may also include the removal of pathogenic bacteria, yeast, or parasites.

Percival M. Intestinal Health. Clin Nutr In. 1997;5(5):1-6.

Fuller R. Probiotics in Human Medicine. Gut. 1991;32: 439-442.

Siitonen S, Vapaatalo H, Salminen S, et al. Effect of Lactobacilli GG Yoghurt in Prevention of Antibiotic Associated Diarrhea. Ann Med. 1990; 22:57-59.

Oksanen P, Salminen S, Saxelin M, et al. Prevention of Travelers' Diarrhea by Lactobacillus GG. Ann Med. 1990; 22:53-56.

Perdigon G, Alvarez M, et al. The Oral Administration of Lactic Acid Bacteria Increases the Mucosal Intestinal Immunity in Response to Enteropathogens. J Food Prot. 1990;53:404-410.

Valeur, N, et al. Colonization and Immunomodulation by Lactobacillus reuteri ATCC 55730 in the Human Gastrointestinal Tract. Appl Environ. Microbiol. 2004 Feb; 70(2):1176-81.

Elmer G, Surawicz C, and McFarland L. Biotherapeutic agents - a Neglected Modality for the Treatment and Prevention of Intestinal and Vaginal Infections. JAMA. 1996; 275(11):870-876.

Fitzsimmons N and Berry D. Inhibition of Candida albicans by Lactobacillus acidophilus: Evidence for Involvement of a Peroxidase System. Microbio. 1994; 80:125-133

Weisburger JH. Proc Soc Exp Biol Med 1999;220(4):271-5.

Dysbiotic Flora

In a healthy balanced state of intestinal flora, the beneficial bacteria make up a significant proportion of the total microflora. However, in many individuals there is an imbalance or deficiency of beneficial flora and an overgrowth of non-beneficial (imbalance) or even pathogenic microorganisms (dysbiosis). This can be due to a number of factors including: consumption of contaminated water or food; daily exposure of chemicals that are toxic to beneficial bacteria; the use of antibiotics, oral contraceptives or other medications; poor fiber intake and high stress levels.

A number of toxic substances can be produced by the dysbiotic bacteria including amines, ammonia, hydrogen sulfide, phenols, and secondary bile acids which may cause inflammation or damage to the brush border of the intestinal lining. If left unchecked, long-term damage to the intestinal lining may result in leaky gut syndrome, allergies, autoimmune disease (e.g. rheumatoid arthritis), irritable bowel syndrome, fatigue, chronic headaches, and sensitivities to a variety of foods. In addition, pathogenic bacteria can cause acute symptoms such as abdominal pain, nausea, diarrhea, vomiting, and fever in cases of food poisoning.

Bacterial sensitivities to a variety of prescriptive and natural agents have been provided for the pathogenic bacteria that were cultured from this patient's specimen. This provides the practitioner with useful information to help plan an appropriate treatment regimen. Supplementation with probiotics or consumption of foods (yogurt, kefir, miso, tempeh, tamari sauce) containing strains of lactobacilli, bifidobacteria, and enterococci can help restore healthy flora levels. Polyphenols in green and ginseng tea have been found to increase the numbers of beneficial bacteria. Hypochlorhydria may also predispose an individual to bacterial overgrowth, particularly in the small intestine. Nutritional anti-inflammatories can aid in reversing irritation to the GI lining. These include quercetin, vitamin C, curcumin, gamma-linoleic acid, omega-3 fatty acids (EPA, DHA), and aloe vera. Other nutrients such as zinc, beta-carotene, pantothenic acid, and L-glutamine provide support for regeneration of the GI mucosa. A comprehensive program may be helpful in individuals in whom a dysbiotic condition has caused extensive GI damage.

Lispki E. Digestive Wellness. New Canaan,CT: Keats Publishing;1996.

Mitsuoka T. Intestinal Flora and Aging. Nutr Rev 1992;50(12):438-446.

Weisburger JH. Tea and Health: The Underlying Mechanisms. Proc Soc Exp Biol Med 1999;220(4):271-275.4.

Pereira SP, Gainsborough N, Dowling RH. Drug-induced Hypochlorhydria Causes High Duodenal Bacterial Counts in the Elderly. Ailment Pharmacol Ther 1998;12(1)99-104.

Murray MT. Stomach Ailments and Digestive Disturbances. Rocklin, CA: Prima Publishing; 1997.

Citrobacter species

Citrobacter species, a gram-negative bacterium and member of the Enterobacteriaceae family, is considered dysbiotic at 3+ - 4+.

Citrobacter freundii complex, including Citrobacter freundii, Citrobacter youngae, Citrobacter braakii, Citrobacter sedlakii, Citrobacter werkmaniii, and less commonly Citrobacter koseri and Citrobacter farmeri, can cause diarrheal disease. Symptoms due to Citrobacter freundii complex seem to be a result of the elaboration of an E. coli-like heat-stable enterotoxin and hydrogen sulfide. Citrobacter freundii complex has been implicated as a cause of gastrointestinal infection and inflammation, acute dysentery, and dyspepsia. Acute symptoms can include profuse, watery diarrhea which is often unaccompanied by abdominal pain, fecal blood, or white blood cells.

Citrobacter species thrive on Fructooligosaccharides (FOS), a common ingredient in artificial or alternative sweetener.

Antibiotics may be indicated if symptoms are prolonged and in systemic infections. Refer to the bacterial sensitivities to identify the most appropriate pharmaceutical or natural agent.

Guarino, A, et al. Production of Eschericia coli Sta-Like Heat-Stable Enterotoxin by Citrobacter freundii Isolated from Humans. Journal of Clinical Microbiology. January 1987;110-114.

Washington W, Allen S, Janda W, Koneman E, Procop G, Schreckenberger P, Woods, G. Koneman's Color Atlas and Textbook of Diagnostic Microbiology, 6th edition. Lippincott Williams and Wilkins; 2006. pg 686-689.

Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH. Manual of Clinical Microbiology, 8th edition. Washington, DC: ASM Press; 2003. pg 701-704.

Klebsiella species

Klebsiella belongs to the Enterobacteriaceae family and is closely related to the genera Enterobacter and Serratia. This gram-negative bacterium is considered dysbiotic in the amount of 3 - 4+.

Klebsiellae are widely distributed in nature and in the gastrointestinal tract of humans. In humans, they may colonize the skin, oral cavity, pharynx, or gastrointestinal tract. Klebsiellae may be regarded as normal flora in many parts of the colon, intestinal tract and biliary tract, but the gut is also the main reservoir of opportunistic strains.

This bacterium has the potential to cause intestinal, lung, urinary tract, and wound infections in susceptible individuals, but Klebsiella overgrowth is commonly asymptomatic. K. pneumoniae, in particular, may cause diarrhea and some strains are enterotoxigenic. Infection has been linked to ankylosing spondylitis as well as myasthenia gravis (antigenic cross-reactivity), and these patients usually carry larger numbers of the organism in their intestines than healthy individuals. Klebsiella oxytoca has been found to be the cause of antibiotic-associated hemorrhagic colitis. These strains have been shown to produce a cytotoxin that is capable of inducing cell death in various epithelial-cell cultures.

Klebsiella is also an infamously known nosocomial infectious agent, partially due to the ability of organisms to spread rapidly. Klebsiella accounts for approximately 3-7% of all hospital-acquired infections, placing it among the top eight pathogens in hospitals. Extraintestinal infection typically involves the respiratory or urinary tracts, but may infect other areas such as the biliary tract and surgical wound sites. K. pneumoniae and K. oxytoca are the two members of this genus responsible for most extraintestinal human infections.

Treatment of these species has become a major problem in most hospitals because of resistance to multiple antibiotics and potential transfer of plasmids to other organisms. Proper hand washing is crucial to prevent transmission from patient to patient via medical personnel. Contact isolation should be used for patients colonized or infected with highly antibiotic-resistant Klebsiella strains.

Klebsiella ozaenae and Klebsiella rhinoscleromatis are infrequent isolates that are subspecies of K. pneumoniae; however, each is associated with at unique spectrum of disease. K. ozaenae is associated with atrophic rhinitis, a condition called ozena, and purulent infections of the nasal mucous membranes. K. rhinoscleromatis causes the granulomatous disease rhinoscleroma, an infection of the respiratory mucosa, oropharynx, nose, and paranasal sinuses.

For the otherwise healthy individual, antimicrobial therapy is often unnecessary. Klebsiella thrives on a diet high in starch, so a low-starch diet may be helpful. A further caution is that Klebsiella thrives on Fructooligosaccharides (FOS) a class of oligosaccharides used as an artificial or alternative sweetener. Antibiotics may be indicated if symptoms are prolonged and in systemic infections. Refer to the bacterial sensitivities to identify the most appropriate pharmaceutical or natural agent.

Hogenauer C, Langner C, Beubler E, et al. Klebsiella oxytoca as a Causative Organism of Antibiotic-Associated Hemorrhagic Colitis. New England Journal of Medicine. December

2006;355;23.

Levy I et al. Nosocomial Infections After Cardiac Surgery in Infants and Children: Incidence and Risk Factors. J Hosp Infect. 2003;53(2):111-6.

Washington W, Allen S, Janda W, Koneman E, Procop G, Schreckenberger P, Woods, G. Koneman's Color Atlas and Textbook of Diagnostic Microbiology, 6th edition. Lippincott Williams and Wilkins; 2006. pg 259-264.

Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH. Manual of Clinical Microbiology, 8th edition. Washington, DC: ASM Press; 2003. pg 688-689.

Dysbiotic Yeast

Yeast was cultured from this stool specimen and the amount is considered to be dysbiotic. A positive yeast culture and sensitivity to prescriptive and natural agents is helpful in determining which anti-fungal agents to use as part of a therapeutic plan for chronic yeast syndrome. When investigating the presence of yeast, disparity may exist between culturing and microscopic examination. Yeast grows in colonies and is typically not uniformly dispersed throughout the stool. This may lead to undetectable or low levels of yeast identified by microscopy, despite a significant amount of yeast cultured.

Microscopic yeast

Microscopic examination has revealed yeast in this stool sample. The microscopic finding of yeast in the stool is helpful in identifying whether the proliferation of fungi, such as Candida albicans, is present. Yeast is normally found in very small amounts in a healthy intestinal tract. While small quantities of yeast (reported as none or rare) may be normal, yeast observed in higher amounts (few, moderate to many) is considered abnormal.

An overgrowth of intestinal yeast is prohibited by beneficial flora, intestinal immune defense (secretory IgA), and intestinal pH. Beneficial bacteria, such as Lactobacillus colonize in the intestines and create an environment unsuitable for yeast by producing acids, such as lactic acid, which lowers intestinal pH. Also, lactobacillus is capable of releasing antagonistic substances such as hydrogen peroxide, lactocidin, lactobacillin, and acidolin.

Many factors can lead to an overgrowth of yeast including frequent use of antibiotics (leading to insufficient beneficial bacteria), synthetic corticosteroids, oral contraceptives, and diets high in sugar. Although there is a wide range of symptoms which can result from intestinal yeast overgrowth, some of the most common include brain fog, fatigue, reccurring vaginal or bladder infections, sensitivity to smells (perfumes, chemicals, environment), mood swings/depression, sugar and carbohydrate cravings, gas/bloating, and constipation or loose stools.

A positive yeast culture (mycology) and sensitivity to prescriptive and natural agents is helpful in determining which anti-fungal agents to use as part of a therapeutic treatment plan

for chronic colonic yeast. However, yeast are colonizers and do not appear to be dispersed uniformly throughout the stool. Yeast may therefore be observed microscopically, but not grow out on culture even when collected from the same bowel movement.

Lysozyme

The level of lysozyme, a biomarker of inflammation, is elevated in this specimen. Lysozyme is an enzyme that catalyzes the hydrolysis of specific glycosidic bonds in mucopolysaccharides that constitute the cell wall of gram-positive bacteria. Lysozyme is an antibacterial defense present in the G.I. tract and is secreted by granulocytes, macrophages, Paneth cells, and Brunner's Glands as well as normal colonic crypt cells [1]. The main source for fecal lysozyme is the intestinal granulocytes.

Moderate elevations in fecal lysozyme are commonly associated with significant overgrowth of enteropathogens such as yeast or dysbiotic bacteria. Markedly elevated levels of fecal lysozyme have been identified in colonic inflammatory bowel disease (IBD), such as Crohn's disease and ulcerative colitis as well as other non-IBD G.I. diseases with diarrhea, compared to healthy controls [2,3]. In Crohn's disease, excess lysozyme may be a result of active secretions of macrophages in the lamina propria, and monocytic cells in the granulomas (sites of G.I. inflammation) [4]. In ulcerative colitis, it has been postulated that elevations in fecal lysozyme may be secondary to intestinal loss of granulocytes and their secretory granules [5]. Additionally, Paneth cell metaplasia, a phenomenon that occurs with various inflammatory conditions of the large intestine, may be a minor contributor to fecal lysozyme elevations [5]. Paneth cells are part of the intestinal epithelial lining found in the deepest part of intestinal cryptwhich are the crypts of Lieberkühn. Paneth cells contain lysozyme in their secretory granules, and combined with their phagocytic capability, help to regulate intestinal microbial flora [5].

Lysozyme is helpful in the determination of colonic inflammatory activity rather than small bowel disease [2]. Slightly elevated levels of lysozyme may be treated with anti-inflammatory agents or by removing the antagonist, such as enteroinvasive microorganisms or allergens. Moderate to high levels of lysozyme (>2,000) may indicate an active inflammatory bowel condition which often requires further testing such as colonoscopy. To rule out IBD, check fecal lactoferrin levels (elevated with IBD).

1. Saito H, Ksajima T, Masuda A, et al. Lysozyme localization in human gastric and duodenal epitheleum. Cell Tissue Res 1988; 251:3-7-313.
2. Van der Sluys Veer A, Brouwer J, Biemond I, et al. Fecal lysozyme in assessment of disease activity in inflammatory bowel disease. Dig Dis & Sci. 1998;43(3):590-5.
3. Klass HJ, Neale G. Serum and faecal lysozyme in inflammatory bowel disease. Gut 1978;19:233-9.
4. Geboes K, Van den Oord JJ, Rutgeerts P, et al. Immunohistochemical identification of lysozyme in pseudopyloric gland metaplasia in Crohn's

disease. Hepatogastroenterology 1986;90:1121-8.
5. Stamp GWH, Poulsom R, Chung LP, et al. Lysozyme gene expression I inflammatory bowel disease. Gastroenterol 1992;103:532-538.

Fecal Lactoferrin

The level of fecal lactoferrin, a biomarker of serious gastrointestinal inflammation, is abnormally high in this fecal sample. Fecal lactoferrin is elevated in association with Inflammatory Bowel Disease (IBD) such as Ulcerative Colitis (UC) or Crohn's Disease (CD)[1,2], but NOT Irritable Bowel Syndrome (IBS)[1,3]. Therefore, assessment of fecal lactoferrin levels enables distinction between IBD and non-inflammatory IBS. Such distinction is critical because, although both IBD and IBS may share some common symptoms such as diarrhea, abdominal cramping and weight loss, the diseases are treated quite differently. IBD may become life threatening, requires life long treatment and possibly surgery. In contrast, IBS is often effectively treated with dietary restrictions, stress reduction and medication.

Gastrointestinal inflammation associated with IBD is associated with increased infiltration of activated neutrophils into the mucosa and increased release of lactoferrin into the gut[1,4,5]. Patients with inflammation of the GI tract, such as IBD (but not IBS), exhibit elevated lactoferrin concentrations in the feces[1].

Clinical studies have shown that fecal lactoferrin levels of healthy persons are similar to IBS patients, but markedly increased in patients with active IBD[1,3]. Patients with IBD oscillate between active and inactive disease states, and fecal lactoferrin levels increase 2-3 weeks prior to onset of clinical symptoms[6]. During remission and effective treatment, fecal lactoferrin decreases significantly. Therefore disease activity, and efficacy of treatment can be monitored by following fecal lactoferrin levels. The test can be ordered separately to track disease activity in patients with IBD.

Moderately elevated levels of fecal lactoferrin can occur, with fecal red blood cells and leukcytes, in association with invasive enterpathogens [7,8]. Such levels would be expected to be much lower than those associated with the active phase of IBD. Therefore, with moderately elevated levels of fecal lactoferrin, one should check for the presence of enteropathogens (eg. Shigella, Campylobacter, Clostridium difficile).

Guidelines for interpreting the results of this test are provided by the results of a large multi-center clinical study which evaluated fecal lactoferrin levels in 180 patients suffering with IBS and IBD (UC and CD) compared to 56 healthy controls.

		FECAL LACTOFERRIN
GROUP	# of SPECIMENS	mean mcg/ml +/- SE
Inactive UC	41	67 +/- 24
Active UC	31	815 +/- 789
Inactive CD	26	239 +/- 83

Active CD	51	672 +/- 242
IBS	31	1.3 +/- 0.3
Healthy Controls	55	1.6 +/- 0.4

1. Kane, S.V., Sandborn, W.J., Rufo, P.A., et al. Am. J. Gastroenterol. (2003)98(6):1309-14.
2. Sugi, K., Saitoh, O., Hirata, I., et al. Am. J. Gastroenterol. (1996)91(5):927-33.
3. Buderus, S., Lohmann, N., Boone, J. et al. Suppl. Gastroenterol. (2002)122:A-219:St392.
4. Baveye, S., Elass, e., Mamurer, J. et al. Clin. Lab. Med. (1999) 37:281-6.
5. Fine, K.D., Ogunji, G., Niehaus, M. et al. Am J. Gastroenterol. (1993):1300-05.
6. Walker, T., Sandborn, W., Boone, J., et al. Am J. Gastroenterol. (2003)98:S246:742
7. Huicho, L., Garaycochea, V., Uchima, N. et al. Ped. Infect. Dis. J. (1997)16(7):644-7.
8. Guerrant, R.L., Araujo, V., Soares, E. et al. J. Clin. Microbiol. (1992)30(5):1238-42.

Secretory IgA (sIgA)

The concentration of sIgA is abnormally high in this fecal specimen. Immunological activity in the gastrointestinal tract can be assessed using secretory immunoglobulin A (sIgA). Secretory IgA is the predominant antibody or immune protein the body manufactures and releases in external secretions such as saliva, tears, and milk [1]. It is also transported through the epithelial cells that line the intestines out into the lumen. Secretory IgA represents the first line of defense of the GI mucosa and is central to the normal function of the GI tract as an immune barrier [1]. As the principal immunoglobulin isotype present in mucosal secretions, sIgA plays an important role in controlling intestinal milieu which is constantly presented with potentially harmful antigens such as pathogenic bacteria, parasites, yeast, viruses, abnormal cell antigens, and allergenic proteins [1].
Secretory IgA antibodies exert their function by binding to antigenic epitopes on the invading microorganism limiting their mobility and adhesion to the epithelium of the mucus membrane [2]. This prevents the antigens from reaching systemic circulation allowing them to be excreted directly in the feces.

Elevated fecal sIgA is an appropriate response to an antigenic presence. Microbial and

microscopic studies of the stool are useful in identifying if bacteria, yeast, or parasites are present. Eradication of the pathogenic microorganisms will bring sIgA back down into the normal range. Elevated sIgA levels have been observed in the absence of bacteria, yeast or parasites, in individuals with atopic conditions such as food allergies, urticaria, and dermatitis.

References:

1. Crago SS, Tomasi TB. Mucosal Antibodies, Food Allergy and Intolerance. Bailliere Tindall/W.B. Saunders 1987;167-89.
2. Roberts JA. Factors predisposing to urinary tract infections in children. Ped Neph 1996;10:517-522.
3. Carins J, Booth C. Salivary immunoglobulin-A as a marker of stress during strenuous physical training. Aviat Space Environ Med 2002;73(12)1203-7.
4. Teodosio MR, Oliveira ECM. Urinary secretory IgA after nutritional rehabilitation. Braz J Med Biolog Res 1999;32-421-426
5. Alverdy J. Effects of glutamine-supplemented diets on immunology of the gut. J Parent Enteral Nutr 1990;14(4):1095-1135.
6. Burke DJ, et al. Glutamine-supplemented total parenternal nutrition improves gut function. Arch Surg 1989;24:2396-2399.
7. Alverdy JA. The effect of total parenternal nutrition on gut lamina propria cells. J Parent. Enteral Nutr 1990;14(suppl).
8. Qamar A, Aboudola S, Warny M, et al. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to clostridium difficile toxin A in mice. Infect Immun 2001;69(4):2762-5.
9. Buts JP, Bernasconi P, Vaerman JP, et al. Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci 1990;35(2):251-6.

Short Chain Fatty Acids (SCFAs)

The relative and/or total amounts of SCFAs are abnormal in this specimen. In infants, microbial colonization and subsequent SCFA production is a gradual process which is largely determined by environmental exposure, maternal gut microflora, breastfeeding, and possibly genetics [1]. The establishment of an adequate distribution of healthy flora in the gut is crucial in the health of both infants and adults because of the ”competitive exclusion” process of dysbiotic flora [1]. Healthy microflora, such as Lactobacillus and Bifidus generate large amounts of SCFAs (acetic, proprionic, butyric, and valeric) which decrease the pH of the intestine and therefore make the environment unsuitable for pathogens, including bacteria and yeast [1]. SCFAs are the end product of the bacterial fermentation process of dietary fiber by beneficial flora in the gut and play an important role in the prevention of intestinal dysbiosis [1].

The amount and types of SCFAs produced by colonic bacteria will depend on factors such as type of fiber consumed and overall intestinal health. For example, more SCFAs in general are produced by gums and pectins than oat fiber or corn bran; more propionate and butyrate are produced by bacterial activity on gums than pectins [2]. Antibiotic-induced diarrhea may be secondary to decreased colonic fermentation of carbohydrates and decreased overall production of SCFAs [3].

Studies show that SCFAs have numerous implications in gut physiology and health. SCFAs decrease inflammation, stimulate healing, and contribute to normal cell metabolism and differentiation [4]. Acetate, propionate and butyrate have been demonstrated to potentially improve the microcirculation in the intestinal mucosa thereby improving its growth and repair [5,6]. Rectal irrigation with SCFAs can result in improvement of ulcerative colitis [7]. Butyrate and propionate contribute to apoptosis of colorectal cells by increasing the production of reactive oxygen species in the gut [8]. Butyrate also has a positive effect on the differentiation of colonocytes, and this may account for the protective effect of dietary fiber against colorectal cancer [9]. Probiotics and increased dietary fiber can improve/normalize SCFA status.

1. Lispki E. Digestive Wellness. New Canaan(CN):Keats Publishing;1996.
2. Titgemeyer EC, Bourquin LD, Fahey GC Jr, et al. Fermentability of various fiber sources by human fecal bacteria in vitro. Am J Clin Nutr 1991;53(6):1418-24.
3. Clausen MR, Bonnen H, Tvede M, et al. Colonic fermentation to short-chain fatty acids is decreased in antibiotic-associated diarrhea. Gastroenterol 1991;101(6):1497-504.
4. Hickman MA. Interventional nutrition for gastrointestinal disease. Clin Tech Small Anim Pract 1998;13(4):211-6.
5. Mortesen FV, Nielsen H, Aalkjaer C, et al. Short chain fatty acids relax isolated resistance arteries from the human ileum by a mechanism dependent on anion-exchange. Pharmacol Toxicoli 1994;75(3-4):181-5.
6. Mortesen FV, Nielsen H, Mulvaney MJ, et al. Short chain fatty acids dilate isolated human colonic reistance arteries. Gut 1990;31(12):1391-4.
7. Breuer RI, Buto SK, Christ ML, et al. Rectal irrigation with short-chain fatty acids for distal ulcerative colitis. Preliminary report. Dig Dis Sci 1991;36(2):185-7.
8. Giardina C, Inan MS. Nonsteroidal anti-inflammatory drugs, short-chain fatty acids, and reactive oxygen metabolism in human colorectal cells. Biochim Biophys Acta 1998;1401(3):277-88.
9. Basson MD, Sgambati SA. Effects of short-chain fatty acids on human rectosigmoid mucosal colonocyte brush border enzymes. Metabolism 1998;47(2):133-4.